Analyst Michael Ulz from Morgan Stanley reiterated a Buy rating on Dyne Therapeutics (DYN – Research Report) and keeping the price target ...

Avidity Biosciences stock surges on expansion of pipeline targeting rare genetic cardiomyopathies and improvements in siRNA ...

Investors consider Dyne Therapeutics' treatments for muscle diseases and strong cash position as a speculative Buy ...

According to the Mayo Clinic, muscular dystrophy is a group of diseases that cause loss of muscle mass and progressive ...

US FDA grants rare paediatric designation to ARTHEx Biotech’s ATX-01 for the treatment of myotonic dystrophy type 1: Valencia, Spain Friday, November 8, 2024, 16:00 Hrs [IST] AR ...

A drug commonly used to treat glaucoma has been shown in zebrafish and mice to protect against the build-up in the brain of the protein tau, which causes various forms of dementia and is ...

There are two options: ‘Don’t tell him on the first date, you’ll scare him off,’ advises friend A. ‘But what if you become ...

Yet exercise can sometimes be deceptive. Years before starting Virta Health, while cofounding the real-estate company Trulia, ...

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and ...

ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression, today announced that the U.S. Food and Drug ...

Hiking up one of the world’s tallest mountains has seen two long-time friends raise thousands to tackle progressive ...

Q3 2024 Earnings Call Transcript November 4, 2024 Vertex Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $4.38, expectations were $4.14. Operator: Good day. And welcome to ...